Skip to main content
. 2018 Dec 13;4(1):156–167. doi: 10.1016/j.adro.2018.08.020

Figure 4.

Figure 4

For patients who received intensity modulated proton therapy for cancer in the thoracic region and for the indicated organs at risk: (a) minimum dose covering 2% and 50% of the targeted structures (D02 and D50) and mean dose calculated from fixed relative biological effectiveness (RBE) dose; (b) the minimum linear energy transfer (LET) covering 2% (L02) and 50% (L50) of the organ, along with the mean LET; (c-e) RBED50, RBEMean, and RBED02 for the McNamara (McN), Wedenberg (WDG), and repair-misrepair-fixation (RMF) models. Sp = spinal.